These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31892344)

  • 21. Uric acid nephrolithiasis: An update.
    Cicerello E
    Urologia; 2018 Aug; 85(3):93-98. PubMed ID: 29687761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
    Kurajoh M; Koyama H; Shoji T; Sumida C; Yamamoto A; Tsutsumi Z; Moriwaki Y; Yamamoto T; Koga M
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):265-71. PubMed ID: 22456297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The treatment of gout and the internal medical treatment of uric acid nephrolithiasis].
    Zöllner N
    Dtsch Med Wochenschr; 1968 Feb; 93(7):310-2. PubMed ID: 4296298
    [No Abstract]   [Full Text] [Related]  

  • 25. Benzbromarone in the treatment of gout.
    Azevedo VF; Kos IA; Vargas-Santos AB; da Rocha Castelar Pinheiro G; Dos Santos Paiva E
    Adv Rheumatol; 2019 Aug; 59(1):37. PubMed ID: 31391099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
    Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
    Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical dissolution therapy for the treatment of uric acid nephrolithiasis.
    Gridley CM; Sourial MW; Lehman A; Knudsen BE
    World J Urol; 2019 Nov; 37(11):2509-2515. PubMed ID: 30810833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Uricosuric agent].
    Ohno I
    Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzbromarone: availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt onbenzbromarone).
    Day R; Lee H; Graham G; Williams K
    N Z Med J; 2013 Sep; 126(1382):124-6. PubMed ID: 24154781
    [No Abstract]   [Full Text] [Related]  

  • 30. Uric acid nephrolithiasis.
    Liebman SE; Taylor JG; Bushinsky DA
    Curr Rheumatol Rep; 2007 Jun; 9(3):251-7. PubMed ID: 17531180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
    Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Summary of the Dutch College of General Practitioners' "Gout" Standard].
    Romeijnders AC; Gorter KJ
    Ned Tijdschr Geneeskd; 2002 Feb; 146(7):309-13. PubMed ID: 11876034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
    Zöllner N; Griebsch A; Fink JK
    Dtsch Med Wochenschr; 1970 Nov; 95(48):2405-12. PubMed ID: 5480261
    [No Abstract]   [Full Text] [Related]  

  • 34. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
    Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
    Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients with gout can be cured in primary care.
    Rees F; Doherty M
    Practitioner; 2014 Dec; 258(1777):15-9, 2. PubMed ID: 25603588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potassium-sodium citrate prevents the development of renal microcalculi into symptomatic stones in calcium stone-forming patients.
    Unno R; Taguchi K; Okada A; Ando R; Hamamoto S; Kubota Y; Zuo L; Tozawa K; Kohri K; Yasui T
    Int J Urol; 2017 Jan; 24(1):75-81. PubMed ID: 27747937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased incidence of diabetes in patients with gout using benzbromarone.
    Niu SW; Chang KT; Ta A; Chang YH; Kuo IC; Hung CC; Chiu YW; Hwang SJ; Lin SF; Lin HY
    Rheumatology (Oxford); 2018 Sep; 57(9):1574-1582. PubMed ID: 29796661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?
    Gravatt L
    N Z Med J; 2013 Sep; 126(1382):118-9. PubMed ID: 24154779
    [No Abstract]   [Full Text] [Related]  

  • 39. Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort.
    Liang N; Sun M; Sun R; Xu T; Cui L; Wang C; Ma L; Cheng X; Xue X; Sun W; Yuan X; Zhang H; Li H; He Y; Ji A; Wu X; Li C
    Arthritis Res Ther; 2019 Sep; 21(1):200. PubMed ID: 31477161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of benzbromarone on hyperlipidemia in gout].
    Marinchev L; Kŭnev K
    Vutr Boles; 1990; 29(5):99-102. PubMed ID: 2080622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.